dc.contributor.author |
Idilman, R |
|
dc.contributor.author |
Demir, M |
|
dc.contributor.author |
Aladag, M |
|
dc.contributor.author |
Erol, C |
|
dc.contributor.author |
Cavus, B |
|
dc.contributor.author |
Iliaz, R |
|
dc.contributor.author |
Koklu, H |
|
dc.contributor.author |
Cakaloglu, Y |
|
dc.contributor.author |
Sahin, M |
|
dc.contributor.author |
Ersoz, G |
|
dc.contributor.author |
Koksal, I |
|
dc.contributor.author |
Karasu, Z |
|
dc.contributor.author |
Ozgenel, M |
|
dc.contributor.author |
Turan, I |
|
dc.contributor.author |
Gunduz, F |
|
dc.contributor.author |
Ataseven, H |
|
dc.contributor.author |
Akdogan, M |
|
dc.contributor.author |
Kiyici, M |
|
dc.contributor.author |
Koksal, AS |
|
dc.contributor.author |
Akhan, S |
|
dc.contributor.author |
Gunsar, F |
|
dc.contributor.author |
Tabak, F |
|
dc.contributor.author |
Kaymakoglu, S |
|
dc.contributor.author |
Akarca, US |
|
dc.contributor.author |
Akarsu, M |
|
dc.contributor.author |
Alkim, H |
|
dc.contributor.author |
Araz, F |
|
dc.contributor.author |
Ates, F |
|
dc.contributor.author |
Aygen, B |
|
dc.contributor.author |
Balik, I |
|
dc.contributor.author |
Barut, HS |
|
dc.contributor.author |
Baysal, B |
|
dc.contributor.author |
Bolat, A |
|
dc.contributor.author |
Celik, I |
|
dc.contributor.author |
Cosgun, S |
|
dc.contributor.author |
Ensaroglu, F |
|
dc.contributor.author |
Gokcan, H |
|
dc.contributor.author |
Gurel, S |
|
dc.contributor.author |
Gursoy, S |
|
dc.contributor.author |
Inkaya, AC |
|
dc.contributor.author |
Kamilli, C |
|
dc.contributor.author |
Kav, T |
|
dc.contributor.author |
Kuruuzum, Z |
|
dc.contributor.author |
Onder, FO |
|
dc.contributor.author |
Ormeci, N |
|
dc.contributor.author |
Ozbakir, O |
|
dc.contributor.author |
Ozenirler, S |
|
dc.contributor.author |
Ozer, B |
|
dc.contributor.author |
Ozkan, H |
|
dc.contributor.author |
Poturoglu, S |
|
dc.contributor.author |
Senates, E |
|
dc.contributor.author |
Simsek, H |
|
dc.contributor.author |
Toka, B |
|
dc.contributor.author |
Unal, H |
|
dc.contributor.author |
Yaras, S |
|
dc.contributor.author |
Yildirim, AE |
|
dc.contributor.author |
Yildirim, B |
|
dc.contributor.author |
Yilmaz, B |
|
dc.contributor.author |
Yilmaz, H |
|
dc.contributor.author |
Yozgat, A |
|
dc.contributor.author |
Yurdaydin, C |
|
dc.date.accessioned |
2022-10-11T13:33:22Z |
|
dc.date.available |
2022-10-11T13:33:22Z |
|
dc.date.issued |
2019 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/76384 |
|
dc.description.abstract |
The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC. |
|
dc.description.abstract |
Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma. |
|
dc.source |
JOURNAL OF VIRAL HEPATITIS |
|
dc.title |
Low recurrence rate of hepatocellular carcinoma following ledipasvir and |
|
dc.title |
sofosbuvir treatment in a real-world chronic hepatitis C patients cohort |
|